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Neural Wiskott-Aldrich syndrome protein
(nWASP) is implicated in human lung
cancer invasion
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Abstract: Lung cancer is one of the most commonly diagnosed cancers with survival much lower in patients
diagnosed with distal metastases. It is therefore imperative to identify pathways involved in lung cancer invasion
and metastasis and to consider the therapeutic potential of agents that can interfere with these molecular
pathways. This study examines nWASP expression in human lung cancer tissues and explores the effect of nWASP
inhibition and knockdown on lung cancer cell behaviour.
Methods: QPCR has been used to measure nWASP transcript expression in human lung cancer tissues. The effect
of wiskostatin, an nWASP inhibitor, on A-549 and SK-MES-1 lung carcinoma cell growth, adhesion, migration and
invasion was also examined using several in vitro functional assays, including ECIS, and immunofluorescence
staining. The effect of nWASP knockdown using siRNA on particular behaviours of lung cancer cells was also
examined.
Results: Patients with high levels of nWASP expression in tumour tissues have significantly lower survival rates. nWASP
transcript levels were found to correlate with lymph node involvement (p = 0.042). nWASP inhibition and knockdown
was shown to significantly impair lung cancer cell growth. nWASP inhibition also affected other cell
behaviours, in SK-MES-1 invasion and A-549 cell motility, adhesion and migration. Paxillin and FAK activity are reduced
in lung cancer cell lines following wiskostatin and nWASP knockdown as shown by immunofluorescence and western
blot.
Conclusions: These findings highlight nWASP as an important potential therapeutic target in lung cancer
invasion and demonstrate that inhibiting nWASP activity using the inhibitor wiskostatin can significantly alter
cell behaviour in vitro.
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Background
Lung cancer is one of the most commonly diagnosed
cancers accounting for 13% of total cases worldwide [1].
It is also one of the leading causes of cancer death
globally with survival rates much lower in patients diag-
nosed with distal metastases [2, 3]. This highlights the
importance of understanding the mechanisms involved in
lung cancer metastasis and considering how molecular
pathways involved in this process could form novel
potential therapeutic targets.
The critical initial steps in lung cancer metastasis in-
volves the detachment and invasion into the surround-
ing tissues of tumour cells which requires changes to
their adhesive and migratory properties [4]. This is
achieved partly through cell polarisation and the exten-
sion of actin-rich membrane structures in the direction
of movement such as filopodia, lamellipodia or invado-
podia which are found in invasive cancer cells. Focal ad-
hesions on the leading edge of these protrusions connect
the actin cytoskeleton in the migrating cells to their
surroundings through the coordination of numerous
signalling and structural proteins, such as integrins,
focal-adhesion kinase (FAK) and paxillin, allowing them
to gain traction and move [5]. The formation of membrane
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protrusions, which are crucial for cell motility, is controlled
by the rearrangement of the actin cytoskeleton [6–10].
nWASP is a 65kDa cytoplasmic protein which re-
sponds to several cellular signalling molecules to medi-
ate actin polymerisation through interactions with the
Actin-related protein 2/3 (Arp2/3) complex. When in-
active, nWASP exists in an auto-inhibited, folded con-
firmation whereby the main catalytic domain, the VCA
domain on the C-terminus, is shielded by the N-
terminus regions. Signalling molecules, such as the small
GTPase Cdc42, bind to and activate nWASP by destabi-
lising the auto-inhibited state and exposing the VCA re-
gion allowing interactions with the Arp2/3 complex
which, when bound to nWASP in conjunction with an
actin monomer, becomes activated and actin polymerisa-
tion can be initiated [11–15]. Through this role, as a re-
organiser of the actin cytoskeleton, nWASP has been
implicated in the control of many cellular processes such
as vesicle trafficking, pathogen infection and neurite ex-
tension to name a few. However, more interestingly with
respect to cancer studies, nWASP has been shown to be
involved in changes to cell morphology, such as invado-
podium formation, growth and also correlates with cer-
tain cancer phenotypes. Hence, nWASP has been
highlighted as a potential therapeutic target in a range of
contexts, particularly in the control of cancer progres-
sion [11, 15–23].
The primary aim of this investigation is to explore the
role and therapeutic potential of targeting nWASP with
reference to lung cancer. This is achieved by examining
the activity of nWASP in human lung cancer tissues and
by studying the effects of nWASP knockdown and the
nWASP inhibitor wiskostatin [24] on lung cancer cell
behaviour, with particular focus towards migratory, inva-
sive, adhesive and proliferative properties.
Methods
Cell lines, culture conditions and tissue samples
A-549 and SK-MES-1 lung carcinoma cell lines were
purchased from ATCC (VA, USA) in October 2014 and
were cultured in Dulbecco’s Modified Eagle Medium
(DMEM) (Sigma-Aldrich, Dorset, UK) supplemented
with 10% foetal bovine serum (FBS). Authentication of
both cell lines took place using STR profiling techniques
and regular testing for mycoplasma contamination was
also carried out.
Ethics, consent and permissions
Fresh frozen lung carcinoma tissues at TNM stages of 1
to 3, with matched normal tissues, were obtained from
150 patients who received curative resection in Peking
University Cancer Hospital from January 2001 to December
2006. Ethical approval was provided by hospital’s Ethics
Committee at Peking University Cancer hospital. Tissues
were collected immediately after surgical resection and
stored in the Tissue Bank of Peking University Oncology
School. Clinicopathological factors, including age, sex,
histological types of tumours, TNM stage, lymph node
metastasis and survival were recorded and stored in the
patients’ database.
siRNA transfection
Cells were seeded in a 24-well plate in serum-free DMEM
(no antibiotics) at 2 × 105 cells/well. After 24 h cells were
transfected with 0.17 μg nWASP siRNA (sc36006, Santa
Cruz Biotechnology Inc., USA), or non-targeting siRNA
(NT), delivered in antibiotic free DMEM supplemented
with 5% FBS with 1 μl Lipofectamine 3000 reagent (Ther-
moFisher Scientific, MA, USA) per well. After a further
24 h cells were then used for RNA/protein extraction or
functional assays.
RNA isolation and QPCR
Total RNA was isolated from the homogenized tissues
(150 pairs of specimens) or from cultured cells using
Total RNA Isolation Reagent (ABgene™). Reverse transcrip-
tion was performed using the Reverse Transcription kit
(Primer design). QPCR was performed on the Icycler IQ5
system (Bio-Rad, Hammel Hemstead, UK) to quantify the
level of nWASP transcripts in the samples (shown as cop-
ies/μl from internal standard normalised to actin). The
QPCR technique utilised the Amplifluor system™ (Intergen
Inc., England) and QPCR master mix (BioRad). nWASP
QPCR primers: Forward: 5’AGTCCCTCTTCACTTTCC
TC’3 and Reverse: 5’ACTGAACCTGACCGTACAACAT
CTCTGTGGATTGTCCT’3. Real-time QPCR conditions
were 95 °C for 15 min, followed by 60 cycles of 95 °C for
20 s, 55 °C for 30 s and 72 °C for 20 s. nWASP transcript
expression was then analysed and correlated with patient’s
pathological and clinical information.
PCR and Gel Electrophoresis
PCR was carried out using the following cycling conditions:
94 °C for 5 min, then 32 cycles of 94 °C for 30s, 55 °C for
40s, 72 °C for 60s with a final extension of 10 min at
72 °C. nWASP primers used: Forward: 5’AGTCCCTCTT
CACTTTCCTC’3 and Reverse: 5’GCTTTTCCCTTCT
TCTTTTC’3. GAPDH primers: Forward: 5’GGCTGCT
TTTAACTCTGGTA’3 and Reverse: 5’GACTGTGGT
CATGAGTCCTT’3. The products were run on a 2% agar-
ose gel and visualised using SYBR safe (Abnova, Taiwan).
Reagents and treatments
Wiskostatin (Enzo Life Sciences, Exeter, UK) was dis-
solved in 30% dimethyl sulfoxide (DMSO, Sigma-Aldrich)
in normal cell culture medium to a stock concentration of
300 μM. Control reactions received appropriate DMSO
treatments. For immunofluorescence and western blot
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assays, the following primary antibodies were used: paxil-
lin BD610052 (BD Biosciences, Oxford, UK), FAK
BD610058 (BD Biosciences, Oxford, UK), pFAK sc11766
(Santa Cruz Biotechnology Inc., USA), nWASP NBP1-
82512 (Novus Biologicals, Abingdon, UK) and GAPDH
sc32233 (Santa Cruz Biotechnology Inc., USA). The sec-
ondary antibodies, AlexaFluor 594 and AlexaFluor 488
(donkey IgG; Life Technologies, Paisley, UK) were used to
conjugate to primary antibodies in immunofluorescence
assays. DAPI (Merck Millipore, Watford, UK) was used to
visualise nuclei. Anti-goat/−mouse/−rabbit IGG whole
molecule peroxidase antibodies (Sigma Aldrich) were used
to conjugate to primary antibodies in Western blot assays.
Protein extraction, SDS-PAGE and Western Blot
Lysis buffer was used to extract protein from cells which
was then used for SDS-PAGE. Proteins were transferred
onto Immobilon® PVDF membranes (Merck Millipore,
Watford, UK) which were blocked and probed with pri-
mary antibodies and then incubated with the corre-
sponding peroxidase conjugated secondary antibodies
(1:1000). Proteins were visualised using EZ-ECL Kit
(Biological Industries, Israel).
In vitro growth assay
Cells were seeded into a 96-well plate with appropriate
treatments at a density of 3000 cells in each well with 10
replicates per treatment. After 1, 2, and 3 day incubation
periods, cells were fixed using 4% formalin (Sigma-Aldrich)
and stained with 1% crystal violet (Sigma-Aldrich). After
washing, crystal violet was extracted from cells using 10%
acetic acid (Sigma-Aldrich) in distilled water (v/v). Absorb-
ance was determined at 540 nm wavelength on an absorb-
ance plate reader (Biotek ELx800).
In vitro cell adhesion assay
Wells on 96-well plates were pre-coated with Matrigel
basement membrane matrix (BD Biosciences) at 50 μg/
ml in normal culture medium. Following rehydration,
8 × 105 cells, which had been incubated overnight in
treatments, were then seeded into each well onto the
Matrigel membrane in 200 μl of normal medium con-
taining treatments with at least 6 replicates per sample
and incubated for 25 min. Adherent cells fixed and
stained as described above and visualised under the
microscope at ×5 magnification.
In vitro scratch assay
7 × 105 cells were seeded in appropriate treatments into
each well on a 24-well plate with at least 3 replicates per
experiment. Upon reaching confluence the monolayer
was scratched to create a linear wound. The plate was
placed in an EVOS® FL Auto Imaging System (Life Tech-
nologies, Paisley, UK) which maintained the plate in
normal culture conditions throughout the experiment.
Images were captured of the wound every 30 min for
up to 24 h.
ECIS assay
Z-theta models of the ECIS (electric cell-substrate im-
pedance sensing) instruments (Applied Biophysics Inc.,
NJ, USA) were used to electrically monitor coverage of
gold electrodes on the base of a 96W1E+ arrays by
measuring the capacitance at 64 kHz. The plate was sta-
bilised and 8 × 104 cells/well were seeded in treatments
where appropriate. At least 4 replicate well were used
for each sample in every experiment. An electrical
wound was applied after 35 h with settings: 20s, current
of 2400 μA and frequency of 60,000 Hz.
Cytodex-2 bead motility assay
Cells were incubated at a density of 7 × 105 cells/ml in
normal culture medium, containing 100 μl of cytodex-2
beads (Sigma-Aldrich at 20 mg/ml in BSS), for 4 h to
allow the cells to adhere to the beads. Following washes,
100 μl of the cell/bead suspension was added to a 96-
well plate and incubated for 18 h in treatments with 6
replicates. Cells which had migrated from the beads to
the plate were fixed, stained and counted according to
absorbance as above.
In vitro invasion assay
Cell culture inserts (8 μm pore ThinCert™ 24-well plate
inserts, Greiner Bio-One GmbH, Austria) were placed
into a 24-well plate and coated with Matrigel basement
membrane matrix (BD Biosciences) at 50 μg/ml in nor-
mal culture medium. Cells were seeded into inserts at a
density of 3 × 104 cells per insert in 200 μl containing
treatments with 3 replicates. After 3 days cells which
had invaded through the Matrigel and migrated through
the pores on the inserts were fixed, stained and counted
according to absorbance as above.
Immunofluorescence staining
For immunofluorescence staining, cells were cultured in
Millicell EZ 8-well chamber slides (Merck Millipore,
Watford, UK) for 18 h at a seeding density of 5 × 104
cells per well. Cells were fixed in 500 μl of ice cold 100%
ethanol at −20 °C. Cells were permeabilised with 0.1%
Triton X 100 (Sigma Aldrich). Primary antibodies (di-
luted to 1:100) and secondary antibodies (1:500 for
Alexa secondary antibodies and 1:1000 for DAPI) were
prepared in blocking buffer in blocking buffer and ap-
plied. Slides were washed and mounted using FluorSave
(Calbiochem, Nottingham, UK) and visualised using an
Olympus BX51 microscope with a Hamamatsu Orca ER
digital camera at × 40. Integrated density was measured
using ImageJ.
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Statistical analysis
Statistical analysis of patient qPCR data was performed
using SPSS software (SPPS Inc.). The relationship between
nWASP and patient clinicopathological information was
assessed using student’s unpaired t-tests. Multivariate ana-
lysis was carried out using Minitab. Survival curves were
produced and analysed using the Kaplan-Meier method
and Wilcoxon (Gehan) statistics. Other data are presented
as mean ± SD. Each experiment was conducted at least 3
times and representative data are presented. Unpaired t-
tests and 2-way ANOVA tests were used to statistically ana-
lyse other experimental data. A p-value <0.05 over at least 3
independent repeats was considered statistically significant.
Results
nWASP expression correlates with patient survival
Multivariate analysis and Kaplan-Meier survival curve ana-
lysis of various lung cancer clinicopathological groups versus
survival demonstrated that TNM staging and nodal status
significantly correlates with patient survival, as expected,
Table 1, Fig. 1b, c. nWASP transcript levels in tumour sam-
ples are also shown to be a factor that correlates with patient
survival, with survival significantly lower in patients which
exhibit high levels of nWASP expression, Table 1, Fig. 1a.
nWASP expression correlates with lung cancer
clinicopathology
Higher levels of nWASP transcript were detected in
squamous carcinoma and adenocarcinoma tumour tissues
compared with small-cell carcinoma tumour samples,
Fig. 2a. nWASP also correlated with lymph node involve-
ment and TNM stage with node positive samples having
significantly higher levels of nWASP expression than node
negative samples, Table 2 and Fig. 2b, c.
nWASP expression in lung tumour tissues and
relationship with patient smoking habits
nWASP expression appears to correlate with patient
smoking habits with long-term smokers that have a
smoking habit of 20-40 years showing increased nWASP
levels compared with patients who have smoked for less
than 20 years, Table 2, Fig. 2d.
Knockdown of nWASP in A-549 and SK-MES-1 cell lines
Since nWASP transcript expression is elevated in adeno-
carcinoma and squamous carcinoma cell lines (Fig. 2a),
A-549 and SK-MES-1 cell lines were selected as models
of these lung cancer sub-types respectively in order to
examine the role of nWASP. nWASP siRNA was used to
significantly knockdown nWASP at 48 h at both gene and
protein level as demonstrated by qPCR, PCR (Fig. 3a, b)
and Western blot (Fig. 3c, d).
ECIS analysis of nWASP inhibition and knockdown in
A-549 and SK-MES-1 cells
ECIS analysis of A-549 and SK-MES-1 cell lines follow-
ing wiskostatin treatment showed that the capacitance
following seeding was significantly increased compared
with the controls in both cell lines, Fig. 4a, d respectively.
This suggests that the initial attachment and spreading be-
haviour of these cells is impaired by nWASP inhibition.
Following an electrical wounding, SK-MES-1 cells are
found to have a significantly increased capacitance follow-
ing nWASP inhibitor treatment, Fig. 4e. No significant
difference between the capacitance of the wiskostatin
treated and control A-549 cells is detected, Fig. 4b. This
suggests that the invasive/migratory capacity of SK-MES-
1 cells following an electrical wounding is impaired by
nWASP inhibition but not in A-549 cells. ECIS analysis of
the healing of an electrical wound using A-549 and SK-
MES-1 nWASP knockdown cell lines demonstrates that
capacitance is significantly increased in both cell lines fol-
lowing siRNA treatment, Fig. 4c, f respectively. Figure 4g
shows that nWASP knockdown is still present in both cell
lines 96 h after siRNA treatment, the time period over
which the ECIS assay takes place.
nWASP affects in vitro growth of lung cancer cells
10 μM wiskostatin treatment was seen to significantly
inhibit cell growth over 3 days in vitro in both A-549
and SK-MES-1 cells according to the absorbance, Fig.
5a, b respectively. This effect on growth was also shown
in nWASP knockdown A-549 and SK-MES-1 cell
lines, with a significant difference detected after 3 days,
Fig. 5c, d respectively.
In vitro motility, migration and adhesion of A-549 cells
are reduced following wiskostatin treatment
Motility and migration in A-549 cells was seen to be sig-
nificantly reduced following 10 μM wiskostatin treat-
ment according to the number of motile cells measured
and the rate of scratch wound closure, Fig. 6b, c respect-
ively. Although motility was consistently reduced, no
Table 1 Multivariate analysis of lung cancer categories against
overall survival
Variables F value P value
Tumour type 0.293 0.590
Differentiation 0.481 0.490
Nodal status 7.778 0.007
TNM staging 7.737 0.007
nWASP 9.546 0.003
Multivariate analysis was carried out to examine clinicopathological parameters
against overall survival of the patients. TNM staging was found to be significantly
linked to patient survival as is expected (p = 0.007). Likewise, nodal involvement
was found to be related to overall survival (p = 0.007). nWASP expression is also
significantly linked to patient survival (p = 0.003)
Significant values are shown in italics
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Fig. 1 Survival of lung cancer patients according to clinicopathological parameters. a Survival is significantly lower in patients that exhibit high
nWASP expression in tumours (p = 0.01). b Survival correlates with TNM staging significantly (p = 0.001). c Survival is significantly lower in patients
which exhibit nodal activity compared with node negative patient tumour samples (p = 0.008)
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Fig. 2 nWASP expression in lung tumour clinical samples. nWASP transcript levels normalised to actin according to clinicopathological information.
a nWASP transcript levels are higher in both squamous and adenocarcinoma tumours compared with small-cell carcinoma samples (p = 0.18 and
p = 0.052 respectively). b nWASP is expressed at significantly higher levels in tumour tissues which exhibit nodal activity compared with lymph
node-negative tumours (p = 0.042). c nWASP transcript expression increases according to tumour grade, p = 0.094 for TNM1 vs. TNM3.
d nWASP expression is higher in lung tumours where patients have a long-term smoking habit. Mean ± SEM are shown
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Table 2 Levels of nWASP transcripts in lung tumour tissues
Category N nWASP level (mean) SEM
Tumour type Squamous carcinoma 51 32.6 23
Adenocarcinoma 68 32.1 15.3
Small-cell carcinoma 3 1.615 0.886
Differentiation High 7 42.8 42.6
Medium High 16 18.84 9.69
Medium 50 45.8 25.1
Medium/low 23 35.5 30.1
Low 16 5.13 3.78
Nodal status Negative 70 8.37 2.9
Positive 62 62.3 25.7
TNM staging stage-1 39 3.12 1.33
stage-2 31 32.8 23.4
stage-3 52 48 26.2
Period as smoker <5 years 2 0.57724 0.0007
5-10 years 6 7 6.39
10-20 years 19 0.521 0.217
20-30 years 29 47.4 30.6
30-40 years 21 49.0 35.9
Mean nWASP transcript expression normalised to actin, SEM and number of patients in category is shown. Expression is presented according to tumour type, level
of differentiation, nodal involvement, tumour stage and patient smoking habit
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Fig. 3 Generation of nWASP knockdown cell lines. A-549 and SK-MES-1 cells were treated with nWASP siRNA/non-targeting siRNA (NT) at 0.5 μg/
ml and then analysed for nWASP expression after 48 h. a QPCR analysis of nWASP transcript expression demonstrates a significant decrease in
expression in siRNA treated cells, n = 4 replicates. b PCR also demonstrates a decrease in nWASP expression. c Quantitative analysis of Western
blots (n = 4) shows significant decrease in nWASP protein expression in both A-549 and SK-MES1 cell lines after 48 h siRNA treatment. d Representative
image showing knockdown of nWASP at protein level in siRNA treated cells at 48 h
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significant difference in motility or migration was found
between wiskostatin treated and control SK-MES-1 cells,
Fig. 6b, c. The level of adhesion was consistently reduced
in both cell types when treated with wiskostatin; how-
ever this finding was only consistently significant in A-
549 cells, Fig. 6a.
In vitro invasion of SK-MES-1 cells is affected by wiskostatin
treatment
The invasive capacity of A-549 and SK-MES-1 cells was
reduced following wiskostatin treatment according to
the in vitro invasion assay data, Fig. 6d, but only signifi-
cantly over all repeats with SK-MES-1 cells. ECIS experi-
ments support this finding where the capacitance is
increased significantly in SK-MES-1 nWASP knockdown
and wiskostatin treated cells, Fig. 4e, f.
Focal adhesions are affected by nWASP activity in lung
cancer cells
Paxillin activity was considerably altered following wis-
kostatin treatment and nWASP knockdown with fewer
paxillin rich adhesions on the perimeter of the treated
cells compared with the controls, Fig. 7a. A decrease in
paxillin activity which correlates with nWASP activity
has also been shown through Western blot analysis of
A-549 and SK-MES-1 knockdown cells after 48 h of
siRNA treatment, Fig. 7b. Paxillin expression was quan-
tified by measuring the integrated density and found to
be significantly reduced in A-549 and SK-MES-1 siRNA
treated cells compared with the non-targeting control
treated cells, Fig. 7d. In addition, FAK activity was exam-
ined in response to nWASP knockdown. FAK and pFAK
was reduced in A-549 nWASP siRNA treated cells
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Fig. 4 The effect of wiskostatin and nWASP knockdown on cell behaviour monitored using ECIS. a Wiskostatin treatment significantly increases
the capacitance of A-549 cells following seeding. b No significant effect is detected following wounding in A-549 cells. c nWASP knockdown causes a
significant increase in capacitance following an electrical wounding. d Wiskostatin also causes a significant increase in capacitance following seeding
in SK-MES-1 cells. e A significant increase in capacitance is also detected in SK-MES-1 cells following an electrical wounding in wiskostatin treated cells.
f This increase in capacitance is also shown in SK-MES-1 nWASP knockdown cells. g PCR using A-549 and SK-MES-1 nWASP knockdown cells following
ECIS demonstrates that decreased nWASP expression in siRNA treated cells is still present at 96 h compared with cells treated with the non-targeting
control siRNA. Significant differences between samples are represented by * (P < 0.05), etc. over the appropriate time-points
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compared with the control cell line, Fig. 7a, b, d. FAK
and pFAK (Tyr 925) levels seemed lower in SK-MES-1
cells and were not significantly affected by nWASP
activity, Fig. 7a, b, d.
Discussion
Analysis of nWASP transcript expression highlights sev-
eral interesting correlations between nWASP levels and
clinical observations of lung cancer, particularly with
phenotypes indicative of invasive and advanced cancers.
Survival has been shown to correlate with TNM staging
and nodal involvement as expected [32], with prognosis
lower in patients with node positive and high TNM stage
cancers. nWASP activity has been shown to correlate
with patient survival with significantly poorer prognosis
for patients who are found to have high levels of
nWASP transcript expression. Furthermore, nWASP
transcript expression levels are shown to correlate with
TNM stage and lymph node involvement highlighting
nWASP as a potential biomarker of more aggressive
lung cancers phenotypes. These findings suggest that
nWASP may be involved in the invasion of cancer cells
to the lymph nodes and the development of more
advanced lung cancers, and hence has a significant
correlation with patient survival.
This study has demonstrated that nWASP levels in tu-
mours may correlate with patient smoking habits. This
is an interesting finding given that smoking is recognised
as a factor related to lung cancer incidence and develop-
ment. The results from this study infer that the elevated
nWASP activity detected in tumours of patients who are
long-term smokers may be related to the development
of particular types of cancer that are more prevalent in
tobacco users.
nWASP levels are elevated in non-small cell carcin-
oma lung cancer tissues compared with small-cell car-
cinomas. As such, A-549 and SK-MES-1 cell lines were
selected as models for the adenocarcinoma and squa-
mous carcinoma lung cancer sub types respectively in
order to carry out further assays to investigate the role
of nWASP in non-small cell lung cancer cell behaviour.
Several in vitro studies were carried out to examine
the effect of nWASP inhibition, using the agent wiskos-
tatin, and knockdown, using siRNA, on the behaviour of
the A-549 adenocarcinoma cell line and the SK-MES-1
squamous carcinoma cell line. Growth was significantly
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Fig. 5 nWASP activity affects A-549 and SK-MES-1 cell growth. a, b nWASP inhibition using 10 μM wiskostatin treatment significantly impairs the
growth of A-549 and SK-MES-1 cells, respectively. c, d A significant effect on growth is also evident after 3 days in nWASP knockdown A-549 and
SK-MES-1 cells, respectively, when compared to non-targeting control treated cells
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impaired in both lung cancer cell lines by nWASP in-
hibitor treatment and knockdown. Furthermore, inva-
sion of SK-MES-1 cell lines is significantly affected by
both in vitro invasion assays and through ECIS analysis
where the healing of an electrical wound is impaired by
nWASP inhibition and knockdown. Wiskostatin appears
not to have an effect on the invasion of A-549 cells in in
vitro invasion assays but ECIS analysis using A-549
nWASP knockdown cells appears to demonstrate that
nWASP activity does affect the invasive/migratory prop-
erties of A-549 cells following an electrical wounding.
This difference could perhaps be because the inhibitor
may not be fully effective on inhibiting nWASP in the
cells after the length of the ECIS experiment or perhaps
by a change in the attachment behaviour of the A-549
cells, as shown in the Matrigel adhesion assay, which
could account for the change in the capacitance. The
motility and migratory properties of A-549 cells appear
to be significantly impaired by nWASP inhibition. These
properties are affected over short time periods of less
than 24 h, at which point no significant effect on A-549
growth following wiskostatin treatment is seen, so this
effect on cell behaviour is considered to be independent
of changes to cell proliferation.
The differences observed in behaviour of these cells
lines in response to nWASP inhibition and knockdown
could be explained by the origins of the A-549 and SK-
MES-1 cell lines. Squamous carcinoma cell types are
more invasive and migratory compared with adenocar-
cinoma cells [25]. It has been shown here that nWASP
expression correlates with more advanced lung cancer
phenotypes and in particular lymph node metastasis. As
such, the effect of nWASP inhibition and knockdown on
invasive cell behaviours may be more apparent in the
more invasive SK-MES-1 squamous carcinoma cell line.
The experiments demonstrate that nWASP activity
has a role in controlling the invasive and migratory be-
haviour of cancer cells, which is supported by previous
studies [16–20], and that the response of the cell lines
used in this study to nWASP inhibition is different. A
reduction in the adhesive properties of both lung cancer
cell types in response to nWASP inhibition was sug-
gested too, although more significantly in A-549 cells.
This effect on the adhesive and spreading properties is
also highlighted in both cell lines through ECIS.
A possible explanation for the effect on adhesion and
other behaviours observed in the A-549 and SK-MES-1
cell lines following nWASP inhibition is provided through
immunofluorescence studies. These demonstrate fewer
paxillin rich adhesions are found on the periphery of both
cell types following nWASP inhibition and knockdown.
Paxillin is a key protein which localises to site of focal
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Fig. 6 In vitro effect of wiskostatin on A-549 and SK-MES-1 invasion, adhesion, motility and migration. a Wiskostatin treatment impairs the ability
of A-549 and SK-MES-1 to adhere to a Matrigel basement membrane over a 25 min period although only with significance in the former cell line.
b From cytodex-2 motility assays, A-549 cell motility found to be significantly impaired by wiskostatin treatment but SK-MES-1 motility is
not significantly affected. c The rate of closure of a scratch wound is reduced in A-549 cells following wiskostatin treatment but no significant effect on
the rate of migration is seen in SK-MES-1 cells. d The capacity of A-549 and SK-MES-1 cells to invade through pores on a Matrigel lined insert
is impaired by wiskostatin treatment but only significantly in SK-MES-1 cells
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adhesions between the cell and its surroundings and an
increase in paxillin signalling has been linked to enhanced
metastatic potential [26–28]. FAK activity, another mol-
ecule which forms and integral part of focal adhesions and
has also been highlighted as a key molecule in lung cancer
invasion and migration [33, 34], is also affected by
nWASP activity in A-549 cells. FAK phosphorylation at
tyrosine 925, which is decreased in nWASP knockdown
A-549 cells, has also been implicated in the control of
FAK-mediated cell migration and cell protrusion, further
highlighting a role of nWASP in cell migration [35]. The
observation of loss of paxillin and FAK activity following
nWASP inhibition is therefore indicative of a reduction in
invasive potential. Previous reports agree with this conclu-
sion which implicates nWASP in the control of membrane
protrusion formation and structure in cancer cells [29–31].
However, direct signalling mechanisms linking nWASP to
the control of focal adhesions are yet to be identified in the
context of lung cancer invasion.
Conclusions
The findings presented in this study suggest that
nWASP inhibition in lung cancer cell types does in fact
alter cell morphology with respect to the level of
paxillin-rich membrane structures the cells are able to
produce. This is may be due to the role of nWASP in
the organisation of the actin cytoskeleton. Since the im-
portance of actin-rich membrane protrusions in cell
movement and cancer invasion is well understood, it is
clear that nWASP is a key molecule of interest with re-
spect to controlling these cell behaviours. From the re-
sults of the functional assays it is even more apparent
that nWASP activity is important in the control of cellu-
lar movement and, when considered alongside findings
showing elevated nWASP levels in metastatic and ad-
vanced stage lung cancer tissues, this study concludes
that nWASP is a key molecule of interest with respect to
lung cancer invasion.
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